Endoplasmic reticulum stress and autophagy as targets for cancer therapy

Cancer Letters

Volumn 275, Issue 2, 2009, Pages 163-169

  Schönthal, Axel H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Apoptosis; Autophagy; BiP; Bortezomib; Calcium imbalance; Celecoxib; CHOP; Combination therapy; ER stress; GADD153; GRP78; HDAC inhibitors; HIV protease inhibitors; Misfolded proteins; Nelfinavir; Proteasome inhibition; SERCA; SERCA inhibition

Indexed keywords

ATAZANAVIR; BORTEZOMIB; CELECOXIB; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; NELFINAVIR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CHEMOTHERAPY; CELL SURVIVAL; DRUG INHIBITION; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL;

EID: 59349111783     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.005     Document Type: Review

References (68)

1. Boyce M., and Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 13 (2006) 363-373
2. Ma Y., and Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nat. Rev. Cancer 4 (2004) 966-977
3. Marciniak S.J., and Ron D. Endoplasmic reticulum stress signaling in disease. Physiol. Rev. 86 (2006) 1133-1149
4. Wu J., and Kaufman R.J. From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ. 13 (2006) 374-384
5. Lee A.S., and Hendershot L.M. ER stress and cancer. Cancer Biol. Ther. 5 (2006) 721-722
6. Vaupel P., and Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9 Suppl 5 (2004) 4-9
7. Chen Z., Lu W., Garcia-Prieto C., and Huang P. The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr. 39 (2007) 267-274
8. Chauhan D., Hideshima T., and Anderson K.C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 465-476
9. Miasari M., Puthalakath H., and Silke J. Ubiquitylation and cancer development. Curr. Cancer Drug Targets 8 (2008) 118-123
10. Lee A.S. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 67 (2007) 3496-3499
11. Pyrko P., Schönthal A.H., Hofman F.M., Chen T.C., and Lee A.S. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 67 (2007) 9809-9816
12. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., and Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 (2008) 230-233
13. Oyadomari S., and Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 11 (2004) 381-389
14. Suzuki T., Lu J., Zahed M., Kita K., and Suzuki N. Reduction of GRP78 expression with siRNA activates unfolded protein response leading to apoptosis in HeLa cells. Arch. Biochem. Biophys. 468 (2007) 1-14
15. Rutkowski D.T., Arnold S.M., Miller C.N., Wu J., Li J., Gunnison K.M., Mori K., Sadighi Akha A.A., Raden D., and Kaufman R.J. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol. 4 (2006) e374
16. Bernales S., McDonald K.L., and Walter P. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLoS Biol. 4 (2006) e423
17. Høyer-Hansen M., and Jäättelä M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ. 14 (2007) 1576-1582
18. Levine B. Cell biology: autophagy and cancer. Nature 446 (2007) 745-747
19. Mathew R., Karantza-Wadsworth V., and White E. Role of autophagy in cancer. Nat. Rev. Cancer 7 (2007) 961-967
20. Mizushima N., Levine B., Cuervo A.M., and Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 451 (2008) 1069-1075
21. Ding W.X., Ni H.M., Gao W., Hou Y.F., Melan M.A., Chen X., Stolz D.B., Shao Z.M., and Yin X.M. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J. Biol. Chem. 282 (2007) 4702-4710
22. Ogata M., Hino S., Saito A., Morikawa K., Kondo S., Kanemoto S., Murakami T., Taniguchi M., Tanii I., Yoshinaga K., Shiosaka S., Hammarback J.A., Urano F., and Imaizumi K. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell. Biol. 26 (2006) 9220-9231
23. Yorimitsu T., Nair U., Yang Z., and Klionsky D.J. Endoplasmic reticulum stress triggers autophagy. J. Biol. Chem. 281 (2006) 30299-30304
24. Kruse K.B., Brodsky J.L., and McCracken A.A. Autophagy: an ER protein quality control process. Autophagy 2 (2006) 135-137
25. Amaravadi R.K., Yu D., Lum J.J., Bui T., Christophorou M.A., Evan G.I., Thomas-Tikhonenko A., and Thompson C.B. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest. 117 (2007) 326-336
26. Adams J., and Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22 (2004) 304-311
27. Gills J.J., Lopiccolo J., Tsurutani J., Shoemaker R.H., Best C.J., Abu-Asab M.S., Borojerdi J., Warfel N.A., Gardner E.R., Danish M., Hollander M.C., Kawabata S., Tsokos M., Figg W.D., Steeg P.S., Dennis P.A., and Nelfinavir. A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13 (2007) 5183-5194
28. Pyrko P., Kardosh A., Wang W., Xiong W., Schönthal A.H., and Chen T.C. HIV protease inhibitors nelfinavir and atazanavir induce glioblastoma cell death by triggering endoplasmic reticulum (ER) stress. Cancer Res. 67 (2007) 10920-10928
29. Fribley A., Zeng Q., and Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 24 (2004) 9695-9704
30. Meister S., Schubert U., Neubert K., Herrmann K., Burger R., Gramatzki M., Hahn S., Schreiber S., Wilhelm S., Herrmann M., Jack H.M., and Voll R.E. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67 (2007) 1783-1792
31. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Dunner Jr. K., Huang P., Abbruzzese J.L., and McConkey D.J. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65 (2005) 11658-11666
32. Obeng E.A., Carlson L.M., Gutman D.M., Harrington Jr. W.J., Lee K.P., and Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood (2006)
33. J. Gills, J. Lopiccolo, M.S. Abu-Asab, R. Shoemaker, J. Borojerdi, and P.A. Dennis, HIV protease inhibitors as cancer therapeutics: Is off the shelf right on target?, AACR, Washington, DC Abstract (2006) 318.
34. Harada M., Hanada S., Toivola D.M., Ghori N., and Omary M.B. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. Hepatology (2008)
35. Denmeade S.R., and Isaacs J.T. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol. Ther. 4 (2005) 14-22
36. Treiman M., Caspersen C., and Christensen S.B. A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. Trends Pharmacol. Sci. 19 (1998) 131-135
37. Ohuchi K., Takahashi C., Hirasawa N., Watanabe M., Fujiki H., and Tsurufuji S. Stimulation of histamine release and arachidonic acid metabolism in rat peritoneal mast cells by thapsigargin, a non-TPA-type tumor promoter. Biochim. Biophys. Acta 1003 (1989) 9-14
38. Hakii H., Fujiki H., Suganuma M., Nakayasu M., Tahira T., Sugimura T., Scheuer P.J., and Christensen S.B. Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis. J. Cancer Res. Clin. Oncol. 111 (1986) 177-181
39. Janssen S., Rosen D.M., Ricklis R.M., Dionne C.A., Lilja H., Christensen S.B., Isaacs J.T., and Denmeade S.R. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 66 (2006) 358-368
40. Koki A.T., and Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9 (2002) 28-35
41. Grösch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736-747
42. Schönthal A.H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 97 (2007) 1465-1468
43. Johnson A.J., Hsu A.L., Lin H.P., Song X., and Chen C.S. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem. J. 366 (2002) 831-837
44. Schönthal A.H. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioblastoma therapy. Neurosurg. Focus 20 (2006) E21, 21-10
45. Schönthal A.H., Chen T.C., Hofman F.M., Louie S.G., and Petasis N.A. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin. Investig. Drugs 17 (2008) 197-208
46. H.-C. Chuang, A. Kardosh, K.J. Gaffney, N.A. Petasis, and A.H. Schönthal, COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro, Mol Cancer (2008) in press.
47. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495-528
48. Bruserud O., Stapnes C., Ersvaer E., Gjertsen B.T., and Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 8 (2007) 388-400
49. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
50. Rodriguez-Gonzalez A., Lin T., Ikeda A.K., Simms-Waldrip T., Fu C., and Sakamoto K.M. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res. 68 (2008) 2557-2560
51. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., and Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115 (2003) 727-738
52. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., and Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 (2007) 859-863
53. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100 (2003) 4389-4394
54. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., Tassone P., Atadja P., Chauhan D., Munshi N.C., and Anderson K.C. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108 (2006) 3441-3449
55. White E. Autophagic cell death unraveled: Pharmacological inhibition of apoptosis and autophagy enables necrosis. Autophagy 4 (2008) 399-401
56. Hoyer-Hansen M., and Jaattela M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ. 14 (2007) 1576-1582
57. Yorimitsu T., and Klionsky D.J. Eating the endoplasmic reticulum: quality control by autophagy. Trends Cell Biol. 17 (2007) 279-285
58. Carew J.S., Nawrocki S.T., Kahue C.N., Zhang H., Yang C., Chung L., Houghton J.A., Huang P., Giles F.J., and Cleveland J.L. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110 (2007) 313-322
59. Maclean K.H., Dorsey F.C., Cleveland J.L., and Kastan M.B. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J. Clin. Invest. 118 (2008) 79-88
60. Briceno E., Calderon A., and Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg. Neurol. 67 (2007) 388-391
61. Nagle D.G., Ferreira D., and Zhou Y.D. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 67 (2006) 1849-1855
62. Ermakova S.P., Kang B.S., Choi B.Y., Choi H.S., Schuster T.F., Ma W.Y., Bode A.M., and Dong Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 66 (2006) 9260-9269
63. Arap M.A., Lahdenranta J., Mintz P.J., Hajitou A., Sarkis A.S., Arap W., and Pasqualini R. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6 (2004) 275-284
64. Misra U.K., Deedwania R., and Pizzo S.V. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J. Biol. Chem. 281 (2006) 13694-13707
65. Shani G., Fischer W.H., Justice N.J., Kelber J.A., Vale W., and Gray P.C. GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol. Cell. Biol. 28 (2008) 666-677
66. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., and Anderson K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA 102 (2005) 8567-8572
67. Nawrocki S.T., Carew J.S., Pino M.S., Highshaw R.A., Andtbacka R.H., Dunner Jr. K., Pal A., Bornmann W.G., Chiao P.J., Huang P., Xiong H., Abbruzzese J.L., and McConkey D.J. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66 (2006) 3773-3781
68. Kardosh A., Golden E.B., Pyrko P., Uddin J., Hofman F.M., Chen C.T., Louie S.G., Petasis N.A., and Schönthal A.H. Aggravated endoplasmic reticulum (ER) stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analog, 2,5-dimethyl-celecoxib. Cancer Res. 68 (2008) 843-851